Login to Your Account



Anthera's Lupus Peptibody Due for Phase III by Early 2013

By Randy Osborne
BioWorld Today Contributing Writer

Tuesday, September 18, 2012
Data sifted from the subset of an otherwise-failed Phase IIb trial helped Anthera Pharmaceuticals Inc. persuade the FDA to bless the planned Phase III lupus program envisioned with blisibimod, a peptibody that targets high levels of B-cell activating factor (BAFF).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription